ARS won FDA approval last week for neffy as an emergency treatment for patients with Type I allergic reactions, including anaphylaxis. It marked a major innovation in epinephrine delivery as the first and only needle-free treatment option for people with severe allergic reactions. neffy could provide an alternative to the popular EpiPen option that utilizes a needle.
Aptar designed Unidose as a single-use, ready-to-use, one-step nasal delivery system. Users can receive their neffy dose in one spray during a severe allergic reaction. During such an event, a healthcare professional, caregiver or user presses a small plunger at the bottom of the device. This releases the drug in a single spray into the nostril.
“The approval of neffy, which uses our Unidose system, and is the first nasally-delivered epinephrine treatment for severe allergic reaction, including anaphylaxis, once again demonstrates Aptar Pharma’s ‘formulation to patient’ focus on helping our customers develop complex, innovative treatments,” stated Gael Touya, president, Aptar Pharma. “When we combine our nasal systems’ capabilities with our Aptar Pharma Services offering, we bring added value to our customers, and aim to provide further convenience for patients and their caregivers worldwide.”
The Aptar delivery platforms offer reliable intranasal delivery for a variety of medicines. They can also integrate with wireless connectivity technologies, according to a news release.
Stephan B. Tanda, Aptar President and CEO, said: “Aptar has been a leader in nasal delivery of medication for more than 30 years. We are proud of our role in the pharma industry to increase the use of nasally delivered medications that help promote adherence and ease of use for patients.”
